4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $29.6250.

A number of equities research analysts have recently weighed in on FDMT shares. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th.

Insider Buying and Selling at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares of the company’s stock, valued at $9,867,817.95. This represents a 10.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. This trade represents a 53.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 200,496 shares of company stock worth $2,240,244. 7.90% of the stock is owned by insiders.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of the company. Jupiter Topco LLC bought a new stake in shares of 4D Molecular Therapeutics in the second quarter worth about $76,466,000. BlackRock Inc. bought a new position in 4D Molecular Therapeutics during the 2nd quarter valued at approximately $60,463,000. Janus Henderson Group PLC lifted its holdings in 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after buying an additional 2,882,508 shares during the period. Trails Edge Capital Partners LP purchased a new stake in 4D Molecular Therapeutics in the 2nd quarter worth approximately $29,631,296. Finally, State Street Corp grew its position in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after buying an additional 1,785,106 shares during the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $14.67 on Monday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $810.37 million, a PE ratio of -5.58 and a beta of 2.73. The business’s 50-day moving average price is $12.21 and its 200-day moving average price is $10.33. 4D Molecular Therapeutics has a 12 month low of $5.97 and a 12 month high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. Sell-side analysts forecast that 4D Molecular Therapeutics will post -4.09 EPS for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.